Hematologic Malignancies Articles

Dual Expression of MYC, BCL2 Associated With Poorer Outcomes in DLBCL
Researchers using cell-of-origin classification connected dual expression of the proteins MYC and BCL2 with poorer survival in patients undergoing chemotherapy for diffuse large B-cell lymphoma.
Expert Explains Next Steps With Advancing CLL Care
Richard R. Furman, MD, discusses the continued evolution of the field of chronic lymphocytic leukemia and how physicians decide on the optimal treatment sequence for their patients.
Stem-Cell Transplant Benefit Limited for Double-Hit Lymphoma Patients in Remission
Daniel J. Landsburg, MD, discusses the management of patients with double-hit lymphoma who have achieved remission.
Clinical Trial Enrollment Needed to Advance MPN Field
Kebede H. Begna, MD, discusses the diagnosis and treatment of patients with myeloproliferative neoplasms, including polycythemia vera, essential thrombocytopenia, and myelofibrosis.
Expert Sheds Light on Rare Complement-Mediated Hematologic Disorders
Ronald S. Go, MD, provides perspective on thrombotic microangiopathy and paroxysmal nocturnal hemoglobinuria, including how community physicians can properly diagnose and treat them.
Emerging BTK Inhibitor Tested in B-Cell Malignancies
BGB-3111, a second-generation BTK inhibitor, is being tested in patients with refractory B-cell lymphoid malignancies in an effort to determine whether the novel oral small molecule is a viable therapeutic option and to better understand its pharmacologic properties.
Sameer A. Parikh, MD, discusses how the International Prognostic Index has assisted physicians with their patients who have CLL, the optimal sequencing of therapies, and other emerging molecular targets in this disease.
FDA Grants Priority Review to Copanlisib for Follicular Lymphoma
The FDA has granted a priority review designation to copanlisib as a treatment for patients with relapsed/refractory follicular lymphoma who have received at 2 least prior therapies, according to Bayer, the manufacturer of the PI3K dual-isoform inhibitor.
Expert Highlights Evolving Approaches for Newly Diagnosed Multiple Myeloma
Prashant Kapoor, MD, discusses the importance of minimal residual disease negativity, using International Myeloma Working Group criteria, and field-changing pivotal data in multiple myeloma.
Ongoing AML Trials of Novel Agents Could Shift Field
Aref Al-Kali, MD, discusses some of the recent advancements, exciting ongoing trials, and largest unanswered questions in AML. 
Publication Bottom Border
Border Publication